Australian Clinical Labs Inflicts Pain With Profit Downgrade, CEO Exit -- Market Talk

Dow Jones

Feb 16

2339 GMT - Australian Clinical Labs' strong cost control in 1H was overshadowed by an earnings downgrade and the departure of CEO Melinda McGrath, says Ord Minnett. Shares of ACL drop 9.5% to A$2.19 in early trading. ACL reported 1H underlying Ebit of A$28.0 million, up some 7% on Ord Minnett's estimate. Underlying net profit was a 9% beat to the bank's forecasts. Still, ACL expects FY 2026 Ebit of A$64 million-A$67 million, representing a 6% downgrade at the midpoint. "Overall, a better-than-expected 1H26 result (on strong cost control) but we expect the focus to be on the downgraded FY 2026 guidance, a weaker set-up for FY 2027 and the CEO exit," analyst Tom Godfrey says. "ACL's share price has declined 9% over the last month into the result and we expect further weakness today." (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

February 15, 2026 18:39 ET (23:39 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2611179063"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2611179063\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2611179063?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-16 07:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611179063","market":"fut","top_or_hot":-1,"title":"Australian Clinical Labs Inflicts Pain With Profit Downgrade, CEO Exit -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2339 GMT - <a href=\"https://laohu8.com/S/ACL.AU\">Australian Clinical Labs</a>' strong cost control in 1H was overshadowed by an earnings downgrade and the departure of CEO Melinda McGrath, says Ord Minnett. Shares of ACL drop 9.5% to A$2.19 in early trading. ACL reported 1H underlying Ebit of A$28.0 million, up some 7% on Ord Minnett's estimate. Underlying net profit was a 9% beat to the bank's forecasts. Still, ACL expects FY 2026 Ebit of A$64 million-A$67 million, representing a 6% downgrade at the midpoint. \"Overall, a better-than-expected 1H26 result (on strong cost control) but we expect the focus to be on the downgraded FY 2026 guidance, a weaker set-up for FY 2027 and the CEO exit,\" analyst Tom Godfrey says. \"ACL's share price has declined 9% over the last month into the result and we expect further weakness today.\" (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 15, 2026 18:39 ET (23:39 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Australian Clinical Labs Inflicts Pain With Profit Downgrade, CEO Exit -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAustralian Clinical Labs Inflicts Pain With Profit Downgrade, CEO Exit -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-16 07:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2339 GMT - <a href=\"https://laohu8.com/S/ACL.AU\">Australian Clinical Labs</a>' strong cost control in 1H was overshadowed by an earnings downgrade and the departure of CEO Melinda McGrath, says Ord Minnett. Shares of ACL drop 9.5% to A$2.19 in early trading. ACL reported 1H underlying Ebit of A$28.0 million, up some 7% on Ord Minnett's estimate. Underlying net profit was a 9% beat to the bank's forecasts. Still, ACL expects FY 2026 Ebit of A$64 million-A$67 million, representing a 6% downgrade at the midpoint. \"Overall, a better-than-expected 1H26 result (on strong cost control) but we expect the focus to be on the downgraded FY 2026 guidance, a weaker set-up for FY 2027 and the CEO exit,\" analyst Tom Godfrey says. \"ACL's share price has declined 9% over the last month into the result and we expect further weakness today.\" (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 15, 2026 18:39 ET (23:39 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7124","symbol_name":"保健护理服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2611179063","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611179063","pubTimestamp":1771198740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2339 GMT - Australian Clinical Labs' strong cost control in 1H was overshadowed by an earnings downgrade and the departure of CEO Melinda McGrath, says Ord Minnett. Shares of ACL drop 9.5% to A$2.19 in early trading. ACL reported 1H underlying Ebit of A$28.0 million, up some 7% on Ord Minnett's estimate. Underlying net profit was a 9% beat to the bank's forecasts. Still, ACL expects FY 2026 Ebit of A$64 million-A$67 million, representing a 6% downgrade at the midpoint. \"Overall, a better-than-expected 1H26 result  but we expect the focus to be on the downgraded FY 2026 guidance, a weaker set-up for FY 2027 and the CEO exit,\" analyst Tom Godfrey says. \"ACL's share price has declined 9% over the last month into the result and we expect further weakness today.\" ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7124":"保健护理服务","ACL.AU":"Australian Clinical Labs Ltd"},"translate_title":"澳大利亚临床实验室利润下调、首席执行官退出带来痛苦——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACL.AU":0.9},"content_text":"2339 GMT - Australian Clinical Labs' strong cost control in 1H was overshadowed by an earnings downgrade and the departure of CEO Melinda McGrath, says Ord Minnett. Shares of ACL drop 9.5% to A$2.19 in early trading. ACL reported 1H underlying Ebit of A$28.0 million, up some 7% on Ord Minnett's estimate. Underlying net profit was a 9% beat to the bank's forecasts. Still, ACL expects FY 2026 Ebit of A$64 million-A$67 million, representing a 6% downgrade at the midpoint. \"Overall, a better-than-expected 1H26 result (on strong cost control) but we expect the focus to be on the downgraded FY 2026 guidance, a weaker set-up for FY 2027 and the CEO exit,\" analyst Tom Godfrey says. \"ACL's share price has declined 9% over the last month into the result and we expect further weakness today.\" (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 15, 2026 18:39 ET (23:39 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}